Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.69 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.46 |
| ▸ | CCKAR | P32238 | 5/20 | 0.43 |
| ▸ | CCKBR | P32239 | 5/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17884371 | 1.00 | GLP1R (0.69) | GLP1RFOLH1CCKARCCKBRNOD1 | |
| SCHEMBL12685763 | 1.00 | GLP1R (0.69) | GLP1RFOLH1CCKARCCKBRNOD1 | |
| SCHEMBL19513174 | 1.00 | GLP1R (0.69) | GLP1RFOLH1CCKARCCKBRNOD1 | |
| SCHEMBL19513172 | 1.00 | GLP1R (0.69) | GLP1RFOLH1CCKARCCKBRNOD1 | |
| SCHEMBL19022113 | 1.00 | GLP1R (0.69) | GLP1RFOLH1CCKARCCKBRNOD1 | |
| SCHEMBL19028012 | 1.00 | GLP1R (0.69) | GLP1RFOLH1CCKARCCKBRNOD1 | |
| SCHEMBL17884363 | 1.00 | GLP1R (0.69) | GLP1RFOLH1CCKARCCKBRNOD1 | |
| SCHEMBL21055932 | 1.00 | GLP1R (0.69) | GLP1RFOLH1CCKARCCKBRNOD1 | |
| SCHEMBL21096841 | 1.00 | GLP1R (0.69) | GLP1RFOLH1CCKARCCKBRNOD1 | |
| SCHEMBL17884370 | 1.00 | GLP1R (0.69) | GLP1RFOLH1CCKARCCKBRNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3236991-B1 | FGF21 DERIVATIVES AND USES THEREOF | NOVO NORDISK AS (DK) | 2019-06-19 | — | — | EP | disclosed |
| US-10124039-B2 | FGF21 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2018-11-13 | — | — | US | disclosed |
| US-20180140673-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2018-05-24 | — | — | US | disclosed |
| US-20180140673-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2018-05-24 | — | — | US | disclosed |
| US-9895417-B2 | FGF21 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2018-02-20 | — | — | US | disclosed |
| US-9895417-B2 | FGF21 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2018-02-20 | — | — | US | disclosed |
| US-20170354713-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK AS (DK) | 2017-12-14 | — | — | US | disclosed |
| US-20170354713-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK AS (DK) | 2017-12-14 | — | — | US | disclosed |
| US-9744213-B2 | FGF21 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2017-08-29 | — | — | US | disclosed |
| US-9744213-B2 | FGF21 derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2017-08-29 | — | — | US | disclosed |
| US-20170182124-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| US-20170182124-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182124-A1 | FGF21 Derivatives and Uses Thereof | FGF2, FGFR1, FGF1 | GLP1R 9/4885FOLH1 693/4885CCKAR 63/4885 |
| US-20180140673-A1 | FGF21 Derivatives and Uses Thereof | FGF2, FGFR1, FGF1 | GLP1R 9/4885FOLH1 693/4885CCKAR 63/4885 |
| US-10124039-B2 | FGF21 derivatives and uses thereof | FGF2, FGFR1, FGF1 | GLP1R 9/4885FOLH1 693/4885CCKAR 63/4885 |
| US-20170354713-A1 | FGF21 Derivatives and Uses Thereof | FGF2, FGFR1, FGF1 | GLP1R 9/4885FOLH1 693/4885CCKAR 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.